Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
1(100.0%)
1Total
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05825612Not Yet Recruiting

EPIRUS FH Reverse Cascade Screening

Role: lead

NCT00416741Completed

Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes (ATTEMPT)

Role: lead

NCT00793364Phase 4Completed

Effect of Plant Stanol Ester-Containing Spread on Estimated Cardiovascular Risk in Comparison to Mediterranean Diet

Role: lead

NCT00416611Completed

IMPlementation of gUideLines for the Management of Arterial hypertenSION. The IMPULSION Study

Role: lead

All 4 trials loaded